Jasper Therapeutics, Inc. (NASDAQ: JSPR), a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases, has appointed two new executives to key leadership roles in regulatory affairs and clinical development. The appointments were announced on September 15, 2026, marking a strategic effort to strengthen its pipeline ahead of potential regulatory milestones.
Lisa Pitt, Pharm.D., M.S.J., has been named Senior Vice President of Regulatory Affairs. With over 25 years of experience in regulatory and medical affairs, Pitt previously served as Vice President of Regulatory Affairs at Aiolos Bio, which was acquired by GlaxoSmithKline. Her background includes leadership roles at NorthSea Therapeutics, Horizon Therapeutics, and Viela Bio, as well as a prior position as Senior Regulatory Health Project Manager at the FDA’s Center for Drug Evaluation & Research, where she managed reviews for IND, NDA, and BLA submissions. Pitt holds a Pharm.D. from the University of Maryland School of Pharmacy and an M.S.J. from Seton Hall Law School.
Shiguang Liu, M.D., Ph.D., has been promoted to Vice President of Clinical Development. With a decade of experience at Sanofi, Liu most recently served as Clinical Lead and Senior Clinical Research Director for rare diseases in renal and metabolic disorders. Previously, he held academic appointments as Assistant Professor at The Kidney Institute at the University of Kansas Medical Center and as research faculty at Duke University School of Medicine. Liu earned his M.D. from Zhengzhou University Medical School and a Ph.D. in Cell Biology from the Chinese Academy of Medical Sciences and Peking Union Medical College.
In addition to the executive appointments, Jasper Therapeutics granted stock options to three new hires, including 243,000 shares of voting common stock at an exercise price of $0.6328 per share. The options vest over a four-year period, with 25% vesting after the first year and the remainder vesting monthly thereafter.
The company remains based in Redwood City, California, continuing its focus on advancing therapies for immune-mediated diseases through its clinical-stage pipeline.
